310 results about "Abnormal cells" patented technology

Disclosed herein are antibody-drug-conjugates (ADC) that allow for delivery and release of topoisomerase inhibitors into desired tissues. The disclosed ADCs include an AsnAsn peptide that facilitates the release of an exatecan derivative by legumain. The antibody-drug-conjugates are useful as therapeutic agents for treating various cancers. Pharmaceutical compositions which include the ADCs are also disclosed, as are methods of treating a tumor or abnormal cell proliferation by administering a therapeutically effective amount of an antibody-drug-conjugate disclosed herein under conditions effective to treat a tumor or abnormal cell proliferation.

The present discloses systems and methods for tissue analysis, biopsy, and treatment utilizing at least exogenous fluorophores and near infrared light. A method is disclosed for optically determining the presence of abnormal cells, such as cancer, in tissue. The method includes applying one or more exogenous fluorophores into tissue in an animal body, wherein the exogenous fluorophores include a targeting moiety formulated to bond with a selected site on abnormal cells. The method includes illuminating the one or more exogenous fluorophores in the tissue with near infrared light from an elongated optical probe to generate fluorescent light from exogenous fluorophores present in the tissue. The method includes receiving fluorescent light generated from the one or more exogenous fluorophores in the tissue. The method includes determining if abnormal cells are present in the tissue based on the fluorescent light generated from the one or more exogenous fluorophores in the tissue.

The present disclosure relates to a method and device for identifying abnormal cell images in cervical cell images. The method comprises: inputting a multi-scale cervical cell image into a pre-trained multi-scale fusion network, wherein the multi-scale cervical cell includes different sizes of the same cervical cell image; extracting key node features of the cervical cell image of each scale in the multi-scale cervical cell image through the multi-scale fusion network; determining the grading results of abnormal cell images in the cervical cell image corresponding to the key node features of the cervical cell image of each scale through the Berthesda grading system; fusing the grading results of abnormal cell images in the cervical cell image of each scale, and outputting the abnormal cell image in the cervical cell image and the abnormal cell image with the highest level in the grading results. The present method can identify and determine abnormal cell images in cervical cell images without manual work, and can grade abnormal cell images.

The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU / OU numbering position 442 (or C442) on an antibody CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.

The invention discloses preparation and application of a novel diagnostic kit for a mitochondrial network regeneration function evaluation test, and in the invention, combined detection of related proteins DRP1, MFN2, OPA1 and TIM23 is carried out by utilizing four mitochondrial networks, so that the mitochondrial regeneration function state of sample cells is judged. The kit disclosed by the invention is used for detecting samples such as human blood, urine, cell cultures and tissues by utilizing an ELISA (Enzyme-Linked Immunosorbent Assay) method. Results show that the kit can accurately detect the content of four proteins so as to judge the function of sample mitochondria. The mitochondrial network regeneration capacity function evaluation kit based on a double-antibody sandwich method in an ELISA method can conveniently and accurately evaluate the mitochondrial network regeneration capacity in a human body specimen. The invention discloses preparation and application of the novel diagnostic kit for evaluating the regeneration function of the mitochondrial network. The diagnostic kit plays an auxiliary role in mitochondrial detection in scientific research and disease diagnosis and treatment. The method is applied to mitochondrial function evaluation in all diseases with abnormal cell mitochondrial functions.

The invention relates to an antibody drug conjugate which is shown in a formula (I) and contains two or more bioactive molecules with different action mechanisms, a preparation method of the antibody drug conjugate, and application of the antibody drug conjugate in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to prevention and / or treatment of tumor diseases. # imgabs0 #

The invention relates to a cell quantification method and device, computer equipment and a storage medium. The method comprises the following steps: extracting cell contour features of an endoscope cell image corresponding to a region of interest through a pre-constructed deep learning model, and separating a cell contour region corresponding to each cell in the endoscope cell image according to the cell contour features; classifying the cell contour region corresponding to each cell through the deep learning model to obtain a cell category of each cell; determining an overall cell quantification result corresponding to the endoscope cell image through the deep learning model according to the cell contour region of each cell; and performing depth feature extraction on the cell contour region of which the cell category is the abnormal cell through the deep learning model, and determining an abnormal cell quantification result according to the depth feature and the cell contour feature of the abnormal cell. By adopting the method, the abnormal condition of the cells can be accurately and efficiently judged.

This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4 / 6 (CDK4 / 6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.

The present invention relates, in part, to methods, compounds, and compositions of KRAS G12D inhibitors in combination with dual RAF / MEK inhibitors for the treatment of abnormal cell growth (e.g., cancer).

The invention relates to the technical field of medical informatization, and particularly discloses a blood disease intelligent diagnosis and treatment data processing system which adopts an image processing technology based on deep learning to perform cell detection on a bone marrow morphological image of a patient object so as to focus on a cell target in the image. The method comprises the following steps: acquiring a cell target, performing multi-level feature extraction on the cell target to capture superficial detail features and trunk features of the cell, and performing significant sparse interactive coding on the superficial detail features and the trunk features to obtain cell feature representation with higher distinction degree, thereby realizing intelligent identification of abnormal cells. Through the mode, the cell characteristics in the blood sample can be automatically identified and analyzed, and rapid detection and diagnosis of abnormal cells are realized, so that a doctor can be assisted to carry out faster and more accurate blood disease diagnosis, and the workload of the doctor is relieved.

The present invention relates to compounds of formula (I)or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.

The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and / or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

The present disclosure relates to compounds of Formula (I′):and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

The invention belongs to the technical field of medical instruments, and discloses a digestive endoscopy diseased region accurate positioning and marking device which comprises a controller, an endoscope hose is fixedly connected to the bottom of the controller, and an instrument insertion opening is formed in the right side of the controller. Through the arrangement of the sleeve, the dye tube, the pressurization air bag and the baffle, after an operator observes a diseased region through the endoscope hose, the operator only needs to align the endoscope hose to the diseased region, and by pressing the pressurization air bag, air in the pressurization air bag enters the dye tube through the inner hose; the baffle can be pushed to rotate outwards under the action of air pressure, meanwhile, methylene blue in the dye tube is sprayed out under the action of air flow, a diseased region is marked, the methylene blue can be absorbed by normal mucous membrane cells, and diseased tissue shows dyeing difference due to abnormal cell function and poor absorption capacity, so that the diseased region is marked. Therefore, the effect of accurate positioning is achieved.

An antibody-drug conjugate as shown in formula I, a preparation method therefor, and a use thereof in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to a use in prevention and / or treatment of tumor diseases.

One example method includes receiving an image of a tissue sample stained with a stain; determining, by a first trained machine learning (“ML”) model using the image, a first set of abnormal cells in the tissue sample; receiving an autofluorescence image of the unstained tissue sample; determining, by a second trained ML model using the autofluorescence image and the first set of cells, a second set of abnormal cells, the second set of abnormal cells being a subset of the first set of abnormal cells; and identifying the abnormal cells of the second set of abnormal cells.

The invention relates to an antibody composition for detecting abnormal CTL (cytotoxic T lymphocyte) cells of hemophagocytic syndrome and application of the antibody composition, and the antibody composition comprises a CD2 antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD56 antibody, a CD57 antibody, a Granzyme B antibody, a Perforin antibody, a TRBC1 antibody and a CD45 antibody. In the technical scheme provided by the invention, key phenotypic characteristics of CTL (Cytotoxic Lymphocyte) can be completely covered by various antibodies aiming at T cell and NK cell surface markers, T large granular lymphocyte markers, cytotoxic granular proteins, T cell receptor constant regions and leukocyte common antigens; wherein the clonality of the CTL cells is judged through the expression level of the TRBC1 antibody, and the cytotoxic function activity of the CTL cells is evaluated through the expression levels of Granzyme B and Perforin.

The present invention provides a ligand compound of a cyclopeptide structure, a nuclide marker thereof, a pharmaceutical composition, and a use, and particularly relates to a ligand compound represented by formula (I) and a nuclide marker thereof. The ligand compound and / or the nuclide marker can be used for diagnosing and / or treating diseases associated with abnormal cell proliferation, and have high stability and good pharmacokinetic characteristics.

Provided are a class of fused ring compounds, and a preparation method therefor and the use thereof. Specifically, provided are a compound of the following formula or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, and a preparation method therefor and the use thereof. The compound can be used as a drug for treating diseases related to abnormal cell proliferation.

The invention provides a medical cell detection method. The medical cell detection method comprises the following steps: S1, collecting a cell image for preprocessing; s2, carrying out structured processing and coding processing on the multi-modal data; s3, performing feature extraction on the cell image and the multi-modal data; s4, fusing the cell image and the multi-modal data; s5, inputting the fused feature vector into a segmentation head of the FastSAM; s6, generating a segmentation mask of the image; s7, judging whether the cells are abnormal or not; s8, re-sampling the abnormal cells for cell culture; s9, collecting a cell image in the cell culture equipment in real time, and preprocessing; s10, inputting the cell image into a FastSAM model, and analyzing various indexes of the cell based on the generated segmentation mask; according to the method, cell images, cases, clinical examination results and other multi-modal data are combined, the characteristics of the cells are known more comprehensively, and the detection accuracy is improved.

The invention relates to the technical field of image processing, in particular to a stomach cancer tissue typing auxiliary recognition method based on digital pathological sections. According to the method, morphological feature recognition is carried out on edge information in a grayscale image of a slice, and normal cell edges and abnormal cell edges are screened out according to the size of morphological feature indexes and the morphology of a cell edge curve. A first abnormal area and a second abnormal area are screened out according to the proximity relation, then enhancement coefficients of the two abnormal areas are calculated and enhanced, and a gastric cancer tissue typing recognition result is obtained according to the enhanced stomach pathology image. According to the invention, the object of the enhancement process is only limited to the abnormal region, and different degrees of enhancement are realized for different types of abnormal regions, so that the calculation amount of the enhancement process is reduced, the enhancement process has pertinence, excessive enhancement cannot be caused, and a clear slice image is obtained for tissue typing identification; and the tissue typing recognition efficiency is improved.

The invention discloses a method for detecting, identifying and counting cerebrospinal fluid cell images, which comprises the following steps of: firstly, acquiring a high-quality digital image of a cerebrospinal fluid cell smear through a microscope, and then revealing edges and other areas for distinguishing cells in the image through gradient value calculation; furthermore, through calculation of a local contrast change rate, microscopic change of the cell image is accurately captured, and normal cells and cells with abnormal forms are effectively distinguished; and furthermore, normal cells and abnormal cells are counted to obtain a counting result, so that medical personnel can be better helped to identify the illness state of the patient, and powerful patient medical record information is provided for subsequent medical assistance.

Methods are disclosed for treating chronic lymphocytic leukemia (CLL), and other diseases, comprising administrating to a patient an anti-CLECL1 antibody or antigen-binding fragment thereof, as soluble molecules or as components of CAR-T cells or as bi- or tetra-specific antibodies that co-ligate T cells or NK cells and abnormal cells in CLL or other diseases or as bi- or tetra-specific antibodies that bind only the B cells in CLL or only abnormal cells in other diseases. Methods are disclosed for determining residual disease after therapy or predicting disease relapse in a patient comprising analyzing a blood or bone sample from a patient treated for the disease for the presence of CLECL1+ PF cells using a monoclonal antibody to CLECL1 or antigen-binding fragment thereof, wherein reappearance of CLECL1+ PF cells in the blood of the patient is indicative of development of resistance to therapy. Monoclonal antibodies to CLECL1 are disclosed.

The embodiment of the application discloses an abnormality detection method and device for cell entering a shell, electronic equipment and a storage medium. The method comprises the following steps: acquiring detection data in the process that a cell entering shell machine drives the cell to enter a battery shell; generating one or more to-be-detected curves according to the detection data; detecting the one or more to-be-detected curves respectively according to historical detection data to obtain a detection result corresponding to each to-be-detected curve; and determining an abnormality result of the cell entering the shell according to the detection result corresponding to each to-be-detected curve. The embodiment of the application can improve the accuracy of the abnormal cell judgment. The above judgment process does not need manual inspection, improves the intelligent degree of the cell detection process, can effectively determine the main abnormal problems in the production process, and can be solved in a targeted manner, thereby improving the accuracy and efficiency of the abnormal detection of the lithium cell entering the shell process.

A camptothecin compound and a conjugate thereof, or a tautomer thereof, an enantiomer thereof, a diastereomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, a preparation method therefor, and use thereof. The compound and the conjugate can be used for treating proliferative diseases related to abnormal cell activity.

Provided is a method for using a sample containing cells collected from a patient to discriminate, with high sensitivity and high accuracy, normal cells and abnormal cells contained in the sample. A sample containing cells collected from a patient is irradiated with electromagnetic waves, an electromagnetic wave scattering spectrum from the cells in the sample is measured, and normal cells and abnormal cells are discriminated on the basis of the characteristics of the electromagnetic wave scattering spectrum. The discrimination uses a trained model in which the electromagnetic wave scattering spectra of normal cells and abnormal cells are trained. The sample may be a living cell, or may be a sample that is immobilized by an alcohol or formalin and dyed. The electromagnetic wave scattering spectrum may use either or both of a scattering spectrum obtained through Rayleigh scattering and a scattering spectrum obtained through Mie scattering.

CD24-positive malignant and benign tumors are treated by administration of a naturally occurring or modified oncolytic Zika virus. Diseases associated with abnormal T cell activation or T cell-mediated autoimmunity, wherein CD24 expression is increased, are also expected to be treated by administration of a naturally occurring or modified oncolytic Zika virus. Also contemplated are compounds and methods for treating and / or preventing Zika virus infection in a subject.

The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

A polymeric nanoparticle is disclosed which comprises:(i) at least one disease-associated antigen which is capable of producing a T-cell response, wherein the disease-associated antigen is encapsulated in the nanoparticle;(ii) at least one adjuvant; and(iii) a dendritic cell targeting moiety which is attached to the outer surface of the nanoparticle.Use of the nanoparticle for treating diseases associated with abnormal cell growth or an infection is also disclosed.

The invention discloses a direct counting method and device for detecting the number of fluorescence-labeled rare abnormal cells in a blood sample. Aiming at the problem that direct counting of low-abundance cells is difficult to realize in a conventional blood container by a traditional detection means, the method realizes rapid and direct counting of rare abnormal cells by performing narrow-band filtering, efficient collection and high signal-to-noise ratio detection on a fluorescence signal emitted by a static blood sample. The device comprises a lighting source module, an exciting light and emitted light narrow-band filtering module, a light beam collimation and beam expansion module, a sample bearing module, an emitted light collection and detection module and a data processing and counting module. Accurate counting of the extremely-low-abundance fluorescence labeling abnormal cells can be completed in a conventional transparent container without flow sorting or complex treatment of a blood sample, and the method has the advantages of being easy and convenient to operate, high in detection speed, suitable for clinical screening and the like.